Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis

Xue, Bing; Liang, Linlang; Chen, Keyan

doi:10.1155/2018/5760849

Cited by 5 publications

(6 citation statements)

References 22 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression of pSTAT3 in CD25 + B cells was higher in uninflamed than paired inflamed CD tissue of the same region, consistent with the regulatory effects of these cells 53 . Regulatory B cells are associated with IL-10 and TGF-β, both upstream of pSTAT3 54,55 . Thus, observed pSTAT3 levels might indicate a protective role for CD25 + B cells in CD.…”

Section: Discussionmentioning

confidence: 99%

Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases

et al. 2019

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis. Each disease is characterized by a diverse set of potential manifestations, which determine patients’ disease phenotype. Current understanding of phenotype determinants is limited, despite increasing prevalence and healthcare costs. Diagnosis and monitoring of disease requires invasive procedures, such as endoscopy and tissue biopsy. Here we report signatures of heterogeneity between disease diagnoses and phenotypes. Using mass cytometry, we analyze leukocyte subsets, characterize their function(s), and examine gut-homing molecule expression in blood and intestinal tissue from healthy and/or IBD subjects. Some signatures persist in IBD despite remission, and many signatures are highly represented by leukocytes that express gut trafficking molecules. Moreover, distinct systemic and local immune signatures suggest patterns of cell localization in disease. Our findings highlight the importance of gut tropic leukocytes in circulation and reveal that blood-based immune signatures differentiate clinically relevant subsets of IBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases

et al. 2019

View full text Add to dashboard Cite

show abstract

“…They are activated with the participation of various cytokines such as TGF-b, IL-6, and IL-23 and are involved in the inflammatory response, immune response to bacterial infection, and autoimmune diseases through the secretion of IL-17, IL-22, and other cytokines. 20 Studies have shown that the expression of Th17 cells and Note: Blood was obtained from the mouse heart. After it was fully anticoagulated, a veterinary hematology analyzer was used to complete the routine blood test within 4 h under RT.…”

Section: Discussionmentioning

confidence: 99%

“…They are activated with the participation of various cytokines such as TGF-β, IL-6, and IL-23 and are involved in the inflammatory response, immune response to bacterial infection, and autoimmune diseases through the secretion of IL-17, IL-22, and other cytokines. 20 Studies have shown that the expression of Th17 cells and its related factors, IL-17 and IL-21, increases in the active stage of UC and increases gradually with increased disease activity. 21 Treg is a type of CD4 + CD25 + FOXP3 + T cell subgroup with negative regulation.…”

Section: Discussionmentioning

confidence: 99%

Treatment and mechanism of fecal microbiota transplantation in mice with experimentally induced ulcerative colitis

Zhang

Liu

et al. 2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Restoring intestinal microbiota dysbiosis with fecal microbiota transplantation is considered as a promising treatment for ulcerative colitis. However, the mechanisms underlying its relieving effects remain unclear. Ulcerative colitis pathogenesis is associated with the involvement of immune cells and inflammatory cytokines. Here, we aimed to investigate the effect of fecal microbiota transplantation on T cell cytokines in a dextran sulfate sodium-induced ulcerative colitis mouse model. Five-aminosalicylic acid (5-ASA) was used as the positive control. Male C57BL/6 mice were randomly assigned to control, model (UC), UC + FMT, and UC + 5-ASA groups. Each group consisted of five mice. The establishment of the mouse model was verified by fecal occult-blood screening and hematoxylin–eosin staining. Results showed that fecal microbiota transplantation reduced colonic inflammation, significantly decreased T helper (Th)1 and Th17 cells, interferon-gamma, interleukin-2 and interleukin-17, as well as significantly increased Th2 and regulatory T (Treg) cells, interleukin-4, interleukin-10, and transforming growth factor-beta, and improved routine blood count. Furthermore, 16S rRNA gene-sequencing analysis showed a significant increase in the relative abundance of genus Akkermansia and a significant decrease in the relative abundance of genus Helicobacter in the ulcerative colitis group. Fecal microbiota transplantation restored the profile of the intestinal microbiota to that of the control group. These findings demonstrated the capability of fecal microbiota transplantation in controlling experimentally induced ulcerative colitis by improving Th1/Th2 and Th17/Treg imbalance through the regulation of intestinal microbiota.

show abstract

“…Similar to helper T cells, they release various cytokines in some autoimmune diseases and tumors that are involved in immune regulation. Previous studies have shown that Breg cells (34) exist in the human body and are involved in the body's negative immune regulation. Specifically, these cells secrete IL-10 and other cytokines by B cells which isolated from the peripheral blood of healthy people (35).…”

Section: Discussionmentioning

confidence: 99%

The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α

Wu¹,

Tan²,

Wei³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: The seroconversion of the hepatitis B antigen is the ideal outcome for long-acting interferon-pegylated interferon-α (Peg-IFN-α) treatment among patients with chronic hepatitis B (CHB). B-cell response plays an important role in the process of hepatitis B antigen clearance, but the specific mechanism by which B-cell improve hepatitis B virus (HBV) is still unclear.Methods: A total of 103 CHB patients participated in this study. The patients received 24 weeks of Peg-IFN-α treatment. Flow cytometry was used to detect B-cell surface markers' cluster of differentiation cluster of differentiation CD19, CD24, and CD27 in the peripheral blood mononuclear cells (PBMCs) of CHB patients before and after 24 weeks of Peg-IFN-α treatment.Results: After 24 weeks of Peg-IFN-α treatment, the content of memory B cells (CD19 + CD27 + ) and effector B cells (CD19 + CD38 + ) increased significantly. Further analysis showed that the clearance of the hepatitis B antigen was correlated with the change value, ΔT, of plasma cells before and after treatment. The B-cell subsets (CD19 + CD24 + ; CD19 + CD40 + ; CD19 + CD40 + ; CD19 + CD80 + ), was also tested and the results showed that CD19 + CD24 + and CD19 + CD80 + content also increased significantly after treatment.Conclusions: After Peg-IFN-α treatment, the B-cell subsets of CHB patients are remodeled. Thus, Peg-IFN-α treatment appears to play an important role in the remodeling of B cell subsets and the clearance of HBV antigens. The results of this study provide a theoretical basis and guidance for the clinical treatment of CHB.

show abstract

Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis

Cited by 5 publications

References 22 publications

Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases

Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases

Treatment and mechanism of fecal microbiota transplantation in mice with experimentally induced ulcerative colitis

The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α

Contact Info

Product

Resources

About